TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05912764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient support
Description: Patients will be supported by nurses before and after intervention and hospital leave
Study: NCT04707495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application (SPSRS)
Description: The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone Application (YouTube)
Description: The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
Study: NCT06048484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: 100 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: 100 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: 150 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: 150 mg orally
Study: NCT05913830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular pressure
Description: The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
Study: NCT04824469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
Study: NCT06048484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified FOLFIRINOX
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)
Study: NCT06151444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Agonist
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT06048484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)
Study: NCT05298124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair
Description: Transcatheter edge-to-edge repair
Study: NCT06151444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-adrenergic receptor agonist
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT05202678

Intervention type: DEVICE
Group type: OTHER
Intervention: AGN1 LOEP
Description: Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
Study: NCT05180383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
Study: NCT05298124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Medical treatment in an intensive care unit
Study: NCT05104307

Intervention type: DEVICE
Intervention: Cardiac Performance System (CPS) Device
Description: CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
Study: NCT05701007

Intervention type: DRUG
Intervention: abiraterone
Description: mCRPC

Intervention type: DRUG
Intervention: enzalutamide
Description: mCRPC

Intervention type: DRUG
Intervention: docetaxel
Description: mCRPC

Intervention type: DRUG
Intervention: apalutamide
Description: mCRPC

Intervention type: DRUG
Intervention: cabazitaxel
Description: mCRPC

Intervention type: DRUG
Intervention: Radium-223
Description: mCRPC

Intervention type: DRUG
Intervention: Lutetium-177
Description: mCRPC

Intervention type: DRUG
Intervention: degarelix
Description: mCSPC

Intervention type: DRUG
Intervention: goserelin
Description: mCSPC

Intervention type: DRUG
Intervention: leuprorelin
Description: mCSPC

Intervention type: DRUG
Intervention: triptorelin
Description: mCSPC
Study: NCT05460611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton HALO 1470nm Non-ablative laser
Description: Patients will be treated with the 1470nm non-ablative laser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton HALO 1470nm Non-ablative laser
Description: Patients will be treated with the 1470nm non-ablative laser.
Study: NCT05309317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections
Description: A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ongoing education
Description: Only a course on Prevention of CAUTI will be given to the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing education
Description: Only a course on Prevention of CAUTI will be given to the control group.
Study: NCT04791410

Intervention type: PROCEDURE
Intervention: microvascular decompression
Description: Microvascular decompression of rostral ventrolateral medulla
Study: NCT04353115

Intervention type: DEVICE
Intervention: Training with Serious game
Description: training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
Study: NCT04342390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
Study: NCT06006650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Description: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Description: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Description: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Study: NCT05616923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Topical cream containing 0.1 mg/g trametinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trametinib
Description: Topical cream containing 0.1 mg/g trametinib
Study: NCT05851196

Intervention type: OTHER
Intervention: Proprioceptive training
Description: A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
Study: NCT05754723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Psychotherapy/Psychoeducation
Description: Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
Study: NCT05440812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling and Training to Advance Individual Recovery Skills (STAIRS)
Description: STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
Study: NCT04792021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Oral formulation: 600 mg sachets of N-acetylcysteine
Study: NCT06192849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
Study: NCT05371925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: one 250LRU sulodexide capsule twice a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulodexide
Description: one 250LRU sulodexide capsule twice a day for 8 weeks
Study: NCT05577923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: Pyrotinib 320mg, PO daily, continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
Study: NCT04821258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MICODIGEST 2.0 supplement
Description: MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo
Study: NCT04078555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703 GEL
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 GEL matched vehicle
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Study: NCT06007183

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CHIKV VLP vaccine booster
Description: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CHIKV VLP vaccine booster
Description: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CHIKV VLP vaccine booster
Description: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo booster
Description: Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
Study: NCT06409065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Program
Description: Meditation and discussion sessions will be audio recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Program
Description: Meditation and discussion sessions will be audio recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Program
Description: Meditation and discussion sessions will be audio recorded
Study: NCT05923814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 prophylaxis
Description: The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
Study: NCT05424016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months

Intervention type: OTHER
Group type: OTHER
Intervention: follow-up
Description: routine follow-up (neurosurgical consultation and an MRI every six months)
Study: NCT06264999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Journey II CR
Description: Implantation of Journey II CR Crucite Retaining Knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Journey II XR
Description: Implantation of Journey II XR Bi Cruciate Retaining Knee
Study: NCT05811624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
Description: 14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day.
Study: NCT06054607

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-amylose maize starch+acetate/butyrate
Description: High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-amylose maize starch
Description: Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
Study: NCT06497595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wegovy (2.4 Mg Dose) + exercise & nutrition
Description: Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wegovy (2.4 Mg Dose) + usual care
Description: Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
Study: NCT06566144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy treatment
Description: The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions